Takeshi Otani

1.1k total citations
48 papers, 889 citations indexed

About

Takeshi Otani is a scholar working on Immunology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Takeshi Otani has authored 48 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Takeshi Otani's work include Immune Cell Function and Interaction (13 papers), T-cell and B-cell Immunology (10 papers) and Immunotherapy and Immune Responses (7 papers). Takeshi Otani is often cited by papers focused on Immune Cell Function and Interaction (13 papers), T-cell and B-cell Immunology (10 papers) and Immunotherapy and Immune Responses (7 papers). Takeshi Otani collaborates with scholars based in Japan, United States and Greece. Takeshi Otani's co-authors include Shuji Nakamura, Ryuichi Motoda, Kunzo Orita, J. Brian de Souza, Kathryn Williamson, J. H. L. Playfair, Kazue Tsuji‐Takayama, Toshiya Inoue, Masashi Kurimoto and Masayoshi Kibata and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Scientific Reports.

In The Last Decade

Takeshi Otani

44 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takeshi Otani Japan 15 411 316 180 138 66 48 889
Hiroyoshi Hattori Japan 17 325 0.8× 435 1.4× 310 1.7× 59 0.4× 47 0.7× 39 989
Curtis J. Henry United States 16 433 1.1× 272 0.9× 213 1.2× 56 0.4× 35 0.5× 49 887
Jane M. Turbov United States 14 338 0.8× 515 1.6× 155 0.9× 74 0.5× 38 0.6× 19 1.0k
Sara Rørvig Denmark 12 548 1.3× 238 0.8× 104 0.6× 48 0.3× 42 0.6× 16 878
Mark Masin Switzerland 7 306 0.7× 500 1.6× 95 0.5× 53 0.4× 62 0.9× 9 789
Hongbo Yu United States 12 717 1.7× 587 1.9× 186 1.0× 65 0.5× 43 0.7× 17 1.2k
Colette Charland United States 15 493 1.2× 288 0.9× 185 1.0× 74 0.5× 101 1.5× 21 1.1k
William E. Munger United States 14 401 1.0× 485 1.5× 218 1.2× 40 0.3× 57 0.9× 20 1.0k
Katharina‐Susanne Spanaus Switzerland 10 410 1.0× 206 0.7× 215 1.2× 59 0.4× 28 0.4× 12 840
Thomas M. Yankee United States 16 486 1.2× 233 0.7× 126 0.7× 54 0.4× 111 1.7× 35 897

Countries citing papers authored by Takeshi Otani

Since Specialization
Citations

This map shows the geographic impact of Takeshi Otani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeshi Otani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeshi Otani more than expected).

Fields of papers citing papers by Takeshi Otani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeshi Otani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeshi Otani. The network helps show where Takeshi Otani may publish in the future.

Co-authorship network of co-authors of Takeshi Otani

This figure shows the co-authorship network connecting the top 25 collaborators of Takeshi Otani. A scholar is included among the top collaborators of Takeshi Otani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeshi Otani. Takeshi Otani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morizawa, Yosuke, Katsuya Aoki, Shinji Fukui, et al.. (2024). Long‐term follow‐up of congenital hydronephrosis in a single‐center study. International Journal of Urology. 31(5). 507–511.
2.
Sakamoto, Keiichi, et al.. (2022). 転移性胃癌に対してPaclitaxel/Ramucirumab併用療法中に難治性の間歇的血尿を来たした1例. Kyoto University Research Information Repository (Kyoto University).
3.
Nishimura, Nobutaka, Makito Miyake, Takuto Shimizu, et al.. (2022). First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer. International Journal of Clinical Oncology. 27(11). 1733–1741. 2 indexed citations
4.
Miyake, Makito, Kiyohide Fujimoto, Masahiro Tanaka, et al.. (2009). IMMUNOCHEMOTHERAPY WITH INTERFERON-α, INTERLEUKIN-2, 5-FLUOROURACIL, AND CIMETIDINE FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA. 60(1). 37–47. 2 indexed citations
5.
Sugimoto, Akira, Motoyuki Suzuki, Takeshi Otani, et al.. (2009). HOZOTs, novel human regulatory T-cell lines, exhibit helper or suppressor activities depending on dendritic cell or anti-CD3 stimulation. Experimental Hematology. 37(12). 1454–1463. 6 indexed citations
6.
Tsuji‐Takayama, Kazue, Motoyuki Suzuki, Mayuko Yamamoto, et al.. (2008). The Production of IL-10 by Human Regulatory T Cells Is Enhanced by IL-2 through a STAT5-Responsive Intronic Enhancer in the IL-10 Locus. The Journal of Immunology. 181(6). 3897–3905. 77 indexed citations
7.
Suzuki, Motoyuki, Akira Sugimoto, Akira Harashima, et al.. (2008). Novel mechanisms of suppressor activity exhibited by cytotoxic regulatory T cell lines, HOZOT. Experimental Hematology. 37(1). 92–100. 8 indexed citations
8.
Otani, Takeshi, Kiyohide Fujimoto, Akihide Hirayama, et al.. (2006). . Journal of Microwave Surgery. 24. 33–37.
9.
Tsuji‐Takayama, Kazue, Takeshi Otani, Toshiya Inoue, et al.. (2006). Erythropoietin induces sustained phosphorylation of STAT5 in primitive but not definitive erythrocytes generated from mouse embryonic stem cells. Experimental Hematology. 34(10). 1323–1332. 11 indexed citations
10.
Otani, Takeshi, Toshiya Inoue, Kazue Tsuji‐Takayama, et al.. (2005). Progenitor analysis of primitive erythropoiesis generated from in vitro culture of embryonic stem cells. Experimental Hematology. 33(6). 632–640. 15 indexed citations
11.
Otani, Takeshi, Kiyohide Fujimoto, Katsunori Yoshida, et al.. (2002). TRANSITION ZONE INDEX IN PREDICTING THERAPEUTIC EFFICACY OF BENIGN PROSTATIC HYPERPLASIA. The Japanese Journal of Urology. 93(1). 20–27. 1 indexed citations
12.
Ozono, S., A. Yamaguchi, Hiroyuki Mochizuki, et al.. (2002). Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer and Prostatic Diseases. 5(2). 128–131. 17 indexed citations
13.
Otani, Takeshi, Yoshiki Hayashi, Kiyohide Fujimoto, et al.. (1999). A New Parameter in Decision Making for Transurethral Electroresection of Benign Prostate Hyperplasia. European Urology. 35(3). 185–191. 12 indexed citations
14.
Otani, Takeshi, et al.. (1997). Interferon‐α and ‐γ Differentially Reduce Rapid Immature T‐Cell Death by Contact with HIV‐1 Carrier Cell Clones In Vitro. Microbiology and Immunology. 41(9). 709–716. 3 indexed citations
15.
Souza, J. Brian de, Kathryn Williamson, Takeshi Otani, & J. H. L. Playfair. (1997). Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. Infection and Immunity. 65(5). 1593–1598. 143 indexed citations
16.
17.
18.
Tsuji, Yukiko, Kikuo Okamura, Hiroshi Ito, et al.. (1993). [Antibiotic prophylaxis for transurethral resection of the prostate--comparison of oral administration therapy with intravenous administration therapy].. PubMed. 39(12). 1145–52. 1 indexed citations
19.
Sakata, Takao, Kanae K. Miyake, T Kinukawa, et al.. (1992). [Clinical evaluation of usefulness of cefixime (200 mg administered once daily) in the treatment of acute uncomplicated cystitis].. PubMed. 38(11). 1337–42. 3 indexed citations
20.
Sur, Pratima, Yoshinobu Matsuo, Takeshi Otani, & Jun Minowada. (1991). Modulation of Methotrexate Cytotoxicity with Natural Interferon upon Human Leukemia Cell Line HL-60. Oncology. 48(6). 469–473. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyoshi Hattori Breakdown of academic impact, for papers by Curtis J. Henry Breakdown of academic impact, for papers by Jane M. Turbov Breakdown of academic impact, for papers by Sara Rørvig Breakdown of academic impact, for papers by Mark Masin Breakdown of academic impact, for papers by Hongbo Yu Breakdown of academic impact, for papers by Colette Charland Breakdown of academic impact, for papers by William E. Munger Breakdown of academic impact, for papers by Katharina‐Susanne Spanaus Breakdown of academic impact, for papers by Thomas M. Yankee
Rankless by CCL
2026